This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia
Study Type
OBSERVATIONAL
Enrollment
10,528
Data will be extracted from July 2009 to the last available database extraction
Many Locations
Multiple Locations, Colombia
Age
Time frame: At Baseline
Sex
Time frame: At Baseline
Co-morbidity
Time frame: At Baseline
Healthcare utilization
Primary Care Physicians visits, Outpatient visits and Hospital admissions
Time frame: Up to 2 years
Proportion of Naive to non-naive patient
Time frame: At Baseline
Dose at first prescription
Time frame: Up to 6 years
Duration of treatment
Time frame: Up to 6 years
Discontinuation
Time frame: Up to 6 years
Switch to another study drug
Time frame: Up to 6 years
Time trends of usage of study medications
Time frame: Up to 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.